GT Biopharma Files 8-K on Security Holder Rights
Ticker: GTBP · Form: 8-K · Filed: Sep 26, 2025 · CIK: 109657
| Field | Detail |
|---|---|
| Company | Gt Biopharma, INC. (GTBP) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
GT Biopharma filed an 8-K on 9/25/25 regarding security holder rights. Check for impacts.
AI Summary
GT Biopharma, Inc. filed an 8-K on September 25, 2025, reporting material modifications to the rights of security holders and financial statements. The company, previously known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates potential changes affecting the rights of GT Biopharma's security holders, which could impact investors' stakes and the company's governance.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights can introduce uncertainty and potential changes in equity structure or voting power.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
- September 25, 2025 (date) — Date of Report
FAQ
What specific modifications were made to the rights of GT Biopharma's security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item information, but the specific details of these modifications are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 25, 2025.
What is GT Biopharma, Inc.'s Standard Industrial Classification (SIC) code?
GT Biopharma, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What were GT Biopharma, Inc.'s former company names?
GT Biopharma, Inc. was formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.
What is the Commission File Number for GT Biopharma, Inc.?
The Commission File Number for GT Biopharma, Inc. is 1-40023.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-09-26 16:15:54
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-25-015725.txt ( ) — 199KB
- gtbp-20250925.xsd (EX-101.SCH) — 3KB
- gtbp-20250925_lab.xml (EX-101.LAB) — 33KB
- gtbp-20250925_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: September 26, 2025 By: /s/ Alan Urban Alan Urban Chief Financial Officer